概括
这项研究介绍了一种针对阿尔茨海默病 (AD) 的新型神经调节装置,该装置使用同步感官刺激来恢复大脑节律. 早期试验显示认知和功能衰退显著减缓,提供了一个新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 老年学是指老年学的学科.
背景情况:
- 传统的阿尔茨海默病 (AD) 治疗侧重于粉样蛋白和蛋白,面临成本,可访问性和疗效方面的挑战.
- 对于神经退行性疾病,需要转向网络级干预的范式转变.
研究的目的:
- 通过使用非侵入性神经调节,为轻度至中度的阿尔茨海默病引入一种新的基于物理学的治疗方法.
- 介绍支持Spectris AD设备的工程原理和临床数据.
主要方法:
- 利用同步视觉和听觉刺激来恢复阿尔茨海默病患者的马频率大脑节奏.
- 在 Spectris AD 设备的开发中利用信号处理和系统工程原理.
- 通过临床试验 (OVERTURE,FLICKER) 评估认知和功能衰退的有效性.
主要成果:
- 功能衰退 (ADCS-ADL) 减少了77%,认知衰退 (MMSE) 减缓了76%.
- 观察到结构性大脑的保存,表明与其他治疗相比,有利的安全性.
- 早期的研究表明,Spectris AD设备的有效性和安全性充满希望.
结论:
- Spectris AD代表了一种新的,可扩展的,在家治疗阿尔茨海默病的治疗方式.
- 这种方法意味着从分子点转向神经治疗中的网络级干预.
- 正在进行的HOPE关键试验的进一步验证预计将证实其作为主流AD治疗的潜力.
相关概念视频
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
Parkinson's Disease: Treatment
385
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
385


